David A. Siegel Immuneering Corp Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$1.28 - $2.75 $318,336 - $683,925
248,700 New
248,700 $318,000
Q2 2022

Aug 15, 2022
SELL
$3.89 - $7.81 $8,558 - $17,182
-2,200 Reduced 16.54%
11,100 $60,000
Q1 2022

May 16, 2022
BUY
$6.47 - $16.99 $86,051 - $225,966
13,300 New
13,300 $86,000

Others Institutions Holding IMRX

# of Institutions
41
Shares Held
4.64M
Call Options Held
0
Put Options Held
0
View Full List

About Immuneering Corp

IMRX Quotes by TradingView
  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $53.8M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email